Results 11 to 20 of about 45,662 (251)
Frontiers in Pharmacology, 2023 Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf +4 more
doaj +1 more source
Linking FHIR-Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System. [PDF]
Learn Health SystABSTRACT Introduction Despite strong evidence supporting guideline‐directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), a significant gap persists in the consistent application of these therapies. This shortfall has prompted organizations like the American College of Cardiology to recommend leveraging electronic ...
LeGrand J +5 more
europepmc +2 more sources
Dose-Response, 2021 It has been proven a close relationship between intestinal microbiota and hypertension. Valsartan is a widely used ARB antihypertensive drug; so far, the effect of valsartan on intestinal microbiota remains largely unexplored.
Ying-Zi Qi +5 more
doaj +1 more source
Therapeutic potential of valsartan in overcoming chemoresistance in human glioblastoma. [PDF]
Sci ProgHu JR +5 more
europepmc +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty +14 more
doaj +1 more source
EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
Рациональная фармакотерапия в кардиологии, 2017 Aim. To study the effect of sacubitril/valsartan compared with valsartan on natriuresis, diuresis, blood pressure (BP) and the level of biomarkers in hypertensive patients.Material and methods.
Zh. D. Kobalava +3 more
doaj +1 more source
The Journal of Clinical Hypertension, 2021 We tested our hypothesis that, in hypertensive patients with higher nocturnal home systolic blood pressure (HSBP) at baseline, a valsartan/cilnidipine (80/10 mg) combination would reduce nocturnal HSBP more markedly than a valsartan/hydrochlorothiazide ...
Takeshi Fujiwara +4 more
doaj +1 more source
Analysis of Nebivolol hydrochloride and Valsartan in Pharmaceutical Dosage Form by High Performance Thin Layer Chromatographic Method [PDF]
, 2011 A simple, accurate and precise high performance thin layer chromatographic method has been developed for the estimation of Valsartan and Nebivolol hydrochloride simultaneously from a tablet dosage form.
Alok Mukerjee +5 more
core +2 more sources
Biomedicines, 2022 This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko +9 more
doaj +1 more source